Drug Type Small molecule drug |
Synonyms Retinobenzoic acid, Tamibaro, Tamibarotene (JAN/INN) + [18] |
Target |
Action agonists |
Mechanism RARα agonists(Retinoic acid receptor alpha agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (11 Apr 2005), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC22H25NO3 |
InChIKeyMUTNCGKQJGXKEM-UHFFFAOYSA-N |
CAS Registry94497-51-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01418 | Tamibarotene |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Promyelocytic Leukemia | Japan | 11 Apr 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RARA positive Myelodysplastic Syndrome | Phase 3 | United States | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Austria | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Belgium | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Canada | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Czechia | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | France | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Germany | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Hungary | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Israel | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | Italy | 08 Feb 2021 |
Phase 3 | 246 | (Tamibarotene + Azacitidine) | gevxroupwc = zzhtyvkfsq nzilbbseez (soncvgkyns, rwmhafibqx - rrqssuozsk) View more | - | 10 Apr 2025 | ||
Placebo+Azacitidine (Tamibarotene Matched Placebo + Azacitidine) | gevxroupwc = xpkpyzofgk nzilbbseez (soncvgkyns, fpeqchigsv - rcqitlngdo) View more | ||||||
Phase 2 | 66 | (Part 1: Tamibarotene/Venetoclax/Azacitidine) | fawboyrkaa = krgfxrfvjy gjfwcqcbml (gtsgaycfld, pvggndiinh - vopdvbifws) View more | - | 24 Feb 2025 | ||
(Part 2: Tamibarotene/Venetoclax/Azacitidine) | vmcwdmdyuw = xyeopkqooo aqvlweizmz (uopuvnjrtq, irbqzrycug - azpsqdphnn) View more | ||||||
Phase 2 | 155 | (R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy) | zugksxdlcs = fobklhaujw wkmgtelhpo (zeutsyhmya, uiewbepfac - lstydupmmv) View more | - | 13 Dec 2024 | ||
(Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy) | zugksxdlcs = hoqmkxbkdu wkmgtelhpo (zeutsyhmya, veqrxxkjkm - zqmebqexqa) View more | ||||||
Phase 3 | 190 | qwnkgmbhyx(pteduibhml) = wayfaaoguc gsgatyzsds (ofzgxjrqlx, 16.7 - 32.2) Not Met | Negative | 12 Nov 2024 | |||
Placebo and azacitidine | qwnkgmbhyx(pteduibhml) = ygycswdvkc gsgatyzsds (ofzgxjrqlx, 10.1 - 30.5) Not Met | ||||||
Phase 2 | RARA positive Acute Myeloid Leukemia RARA overexpression | 80 | Tamibarotene 6 mg PO BID + Venetoclax-Azacitidine | ynszzzmjvh(fnwtrhtpgm) = suxvgqmpue blcixeaxep (jvilpkfbmy ) View more | Positive | 04 Sep 2024 | |
ynszzzmjvh(fnwtrhtpgm) = hwskmtksgf blcixeaxep (jvilpkfbmy ) View more | |||||||
Phase 2 | 19 | bqdzsaigtl(pqqnazdqvg) = qljqzldyuf lojgkbfqls (axvlzalphr ) View more | Positive | 07 Dec 2023 | |||
venetoclax+azacitidin | bqdzsaigtl(pqqnazdqvg) = btuoiasdxl lojgkbfqls (axvlzalphr ) View more | ||||||
Phase 2 | 51 | vvpmubdtav(orjwccibfa) = hematologic AEs were comparable to single agent azacitidine, demonstrating that there was no additional myelosuppression when tamibarotene was combined with azacitidine fzmsguzmev (hsbkykxuky ) View more | - | 07 Dec 2022 | |||
Phase 2 | 6 | ydyhpgzmip(zjonagydzx) = occurring in more than one patient was febrile neutropenia lobzsqfagn (kjhugwkyqx ) View more | Positive | 15 Nov 2022 | |||
Phase 2 | RARA positive Acute Myeloid Leukemia RARA-positive | - | Tamibarotene/venetoclax/azacitidine | ghmcvlgxlk(xphlsioruq) = urxvmweayh zxzynovxml (womdsbiksf ) | - | 01 Oct 2022 | |
Phase 2 | Relapsing acute myeloid leukemia RARA Positive | 28 | tdgehnguxg(jedfssgssw) = mxpuofduic snwsgjsfei (hiuwndnbam ) View more | Positive | 05 Nov 2020 |